Raymond James & Associates Ngm Biopharmaceuticals Inc Transaction History

Raymond James & Associates

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	SELL	$0.6 - $1.31 $725 - $1,583	-1,209 Reduced 5.51%	20,714 $17,000
Q3 2023 Oct 24, 2023	SELL	$1.05 - $3.37 $325 - $1,044	-310 Reduced 1.39%	21,923 $23,000
Q2 2023 Jul 25, 2023	SELL	$2.44 - $4.53 $15,476 - $28,733	-6,343 Reduced 22.2%	22,233 $57,000
Q1 2023 Apr 14, 2023	BUY	$3.72 - $5.4 $1,127 - $1,636	303 Added 1.07%	28,576 $116,000
Q4 2022 Feb 08, 2023	SELL	$3.41 - $12.93 $229,878 - $871,650	-67,413 Reduced 70.45%	28,273 $141,000
Q3 2022 Oct 25, 2022	BUY	$12.59 - $17.67 $310,847 - $436,272	24,690 Added 34.78%	95,686 $1.25 Million
Q2 2022 Aug 12, 2022	BUY	$10.58 - $17.5 $85,782 - $141,890	8,108 Added 12.89%	70,996 $910,000
Q1 2022 May 11, 2022	BUY	$13.81 - $18.6 $868,483 - $1.17 Million	62,888 New	62,888 $959,000
Q2 2021 Aug 11, 2021	SELL	$15.06 - $30.03 $1.22 Million - $2.42 Million	-80,692 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$24.99 - $31.93 $470,236 - $600,826	18,817 Added 30.41%	80,692 $2.35 Million
Q4 2020 Feb 12, 2021	SELL	$16.21 - $31.44 $39,017 - $75,676	-2,407 Reduced 3.74%	61,875 $1.88 Million
Q3 2020 Nov 04, 2020	BUY	$15.59 - $19.97 $99,588 - $127,568	6,388 Added 11.03%	64,282 $1.02 Million
Q2 2020 Jul 28, 2020	BUY	$11.97 - $23.47 $692,991 - $1.36 Million	57,894 New	57,894 $1.14 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.